QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.107.120428v1 321/3/866    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simon, W. A. Articles by Postius, S. Search for Related Content PubMed PubMed Citation Articles by Simon, W. A. Articles by Postius, S.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Soraprazan: Setting New Standards in Inhibition of Gastric Acid Secretion

Department of Biochemistry Gastroenterology (W.A.S., M.H., T.K.), Pharmacokinetics/Pharmacometrics (R.H.), External Chemistry (J.S.-B.), and Pharmacology Gastroenterology (S.P.), ALTANA Pharma AG, Konstanz, Germany; and David Geffen School of Medicine, University of California at Los Angeles, and VA Greater Los Angeles Healthcare System, Los Angeles, California (J.M.S.)

Received January 24, 2007; accepted March 14, 2007.

	Abstract

Top Abstract Methods and Materials Results Discussion References

 
After treatment of millions of patients suffering from gastroesophageal reflux disease (GERD) and other acid-related ailments with proton pump inhibitors, there are still unmet medical needs such as rapid and reliable pain relief, especially for nocturnal acid breakthrough. In this work, we introduce and characterize the biochemistry and pharmacology of the potassium-competitive acid blocker (P-CAB) soraprazan, a novel, reversible, and fast-acting inhibitor of gastric H,K-ATPase. Inhibitory and binding properties of soraprazan were analyzed together with its mode of action, its selectivity, and its in vivo potency. This P-CAB has an IC₅₀ of 0.1 µM if measured with ion leaky vesicles and of 0.19 µM in isolated gastric glands. With a K_i of 6.4 nM, a K_d of 26.4 nM, and a B_max of 2.89 nmol/mg, this compound is a highly potent and reversible inhibitor of the H,K-ATPase. Soraprazan shows immediate inhibition of acid secretion in various in vitro models and in vivo and was found to be more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases. Soraprazan is superior to esomeprazole in terms of onset of action and the extent and duration of pH elevation in vivo in the dog. Rapid and consistent inhibition of acid secretion by soraprazan renders the P-CABs a promising group of compounds for therapy of GERD.

The gastric H,K-ATPase is a P₂-type ATPase. This enzyme is responsible for secretion of H⁺ into the secretory canaliculus of the parietal cell by electroneutral exchange of H⁺ for K⁺ (Ganser and Forte, 1973; Sachs et al., 1976). Inhibition of the enzyme is accepted currently as being the best target for medical treatment of acid-related diseases as it is the final step of acid secretion.

As dephosphorylation of the enzyme is dependent on the presence of potassium (Stewart et al., 1981), an alternative means of inhibition of the H,K-ATPase is to block the access of potassium to the ion binding site, competitively or noncompetitively (Wallmark et al., 1987; Vagin et al., 2002, 2003). The discovery that tertiary amines were K⁺-competitive inhibitors of the ATPase (Im et al., 1984) led to the elucidation of the mechanism of an imidazo-[1,2] pyridine, SCH28080, that was a potent inhibitor of this type (Beil et al., 1986; Wallmark et al., 1987). Other imidazo-[1,2] pyridines, such as pumaprazole (von Büdingen et al., 1996), were synthesized and have structures that provide an alternative means of pump inhibition. These particular imidazopyridines bind to the E₂P form of the enzyme and are strictly K⁺-competitive (Mendlein and Sachs, 1990). This mechanism allows rapid inhibition of the pump without the need for acidity at its luminal surface since the pump is blocked in mid-cycle.

Several structural derivatives were tested as inhibitors of the H,K-ATPase, allowing development of a model of the active conformation of SCH28080, in which the benzene ring was orthogonal to the imidazopyridine. The generation of a bridged structure such as a naphthyridine promised greater efficacy than the more flexible SCH28080. This was achieved with the synthesis of soraprazan [BYK61359, (7R,8R,9R)-2, 3-dimethyl-8-hydroxy-7 (2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo-[1,2-h][1,7]-naphthyridine].

Here, we describe the properties of this reversible inhibitor of the H,K-ATPase. Soraprazan is purely K⁺-competitive and therefore has been named a potassium-competitive acid blocker (P-CAB) (Senn-Bilfinger et al., 2006). A more general term for reversible H,K-ATPase inhibitors would be acid pump antagonists (APAs) because not all of these will be strictly K⁺-competitive. This nomenclature has been used previously for the naphthyridine discussed here (Shin et al., 2005).

The aim of this study was to characterize the potency, affinity, and mode of action of this naphthyridine inhibitor. This work demonstrates that soraprazan is a selective K⁺-competitive inhibitor of the H,K-ATPase with convincing in vitro and in vivo potency.

	Methods and Materials

Top Abstract Methods and Materials Results Discussion References

 
Hog Gastric H,K-ATPase Enzyme Preparation. The gastric H,K-ATPase was derived from hog gastric mucosa by a previously published method, which involves differential and density gradient centrifugation (Rabon et al., 1988). Briefly, all operations were carried out at 1 to 4°C. The gastric mucosa was stripped from the stomach fundus and homogenized in a solution of 0.25 M sucrose, 5 mM PIPES/Tris, pH 6.8, 1 mM EDTA, and 1 mM EGTA. The homogenate was centrifuged at 11,000 rpm in a Sorvall GSA rotor for 45 min. The pellet was discarded, and the supernatant was centrifuged at 34,000 rpm in a Beckman type 35 rotor for 1 h. The microsomal membrane pellet was resuspended in a solution of 0.25 M sucrose, 5 mM PIPES/Tris, pH 6.8, 1 mM EDTA, and 1 mM EGTA, and was purified on a Ficoll/sucrose step gradient; composed of 34% (w/v) sucrose, 5 mM PIPES/Tris, pH 6.8, 1 mM EDTA, and 1 mM EGTA overlaid by a solution composed of 7.5% Ficoll, 0.25 M sucrose, 5 mM PIPES/Tris, pH 6.8, 1 mM EDTA, and 1 mM EGTA, using a SW28 rotor at 27,000 rpm for 2 h. The ion-tight vesicle fraction above the 7.5% Ficoll gradient was collected and diluted by adding 3 volumes excess of a solution of 5 mM PIPES/Tris, pH 6.8, 1 mM EDTA, and 1 mM EGTA. The suspension was centrifuged at 100,000g for 1 h, and the pellet was resuspended in a solution of 0.25 M sucrose and 5 mM PIPES/Tris, pH 6.8.

The vesicles obtained have been shown to be >90% cytoplasmic side out (Shin et al., 2005). The Mg²⁺-dependent activity was approximately 5.7 µmol/mg/h. The ion impermeability of the vesicles was determined by the difference in K⁺ stimulation of ATPase activity in the presence of KCl alone and in the presence of KCl and the ionophore, nigericin, that allows K⁺ penetration to the luminal surface of the pump. The activity in the presence of nigericin was 105 µmol of ATP hydrolyzed/mg of protein/h and in the absence of nigericin was only 7.6 µmol/mg protein/h. Thus, >90% of the K⁺-stimulated ATPase activity was dependent on the addition of the K⁺ ionophore, nigericin, showing that this fraction of the vesicles was K⁺-impermeant. P_i released was measured by the method of Yoda and Hokin (1970) and protein concentration was determined by a modified Lowry method (Lowry et al., 1951) with 0.1% SDS.

H,K-ATPase Activity in Ion-Leaky Gastric Vesicles. One microgram of protein was incubated in the presence of 1 mM Mg-ATP in 100 mM Pipes-200 mM Tris-HCl buffer, pH 7.4, 250 mM sucrose, and 0.5 to 5.0 mM KCl. Soraprazan was used in nanomolar concentrations for K_i calculation and at 10^–4 to 10^–9 M for IC₅₀ determination. The reaction was terminated by addition of a 2:1 mixture of 4.5% (w/v) malachite green and 42 g/liter ammonium molybdate. The phosphomolybdate complex was measured at 690 nm in a multiwell spectrophotometer, as described previously (Vagin et al., 2002). Graphic determination of K_i was performed according to Dixon (1953). IC₅₀ values were calculated with the help of GraphPad Prism (version 4.02; GraphPad Software Inc., San Diego, CA).

Proton Transport Activity. Acidification of the gastric vesicles was measured by the quenching of acridine orange. The vesicles at 10 µg/ml were suspended in a medium containing 250 mM sucrose, 150 mM KCl, 3 mM MgCl₂, 1 µM acridine orange, 4 mM PIPES-8 mM Tris buffer. pH 7.4, and 10 µg of valinomycin to allow K⁺ access to the interior of the vesicles. Transport was initiated by the addition of 2 mM ATP (pH 7.4), and the fluorescence of acridine orange was measured over time at an excitation wavelength of 480 nm and emission at 530 nm (Rabon et al., 1978; Wolosin and Forte, 1981) in a VICTOR³ multilabel counter from Perkin Elmer. The inhibitors were added at the indicated concentrations after maximal acidification of the vesicles 30 min after start of the reaction by ATP.

Reversibility. Reversibility experiments were carried out with ion-leaky gastric vesicles as described above. To measure the reversibility of inhibition by soraprazan in the presence of 1 mM KCl, recovery of H,K-ATPase activity after dilution of the incubation mixture was measured. The starting concentration was 2.5 µM soraprazan in two independent experiments conducted in triplicate, and the dilutions were 2-, 5-, 10-, 20-, 50- and 100-fold at constant KCl. H,K-ATPase activity was set to 100% at any dilution without inhibitor.

[¹⁴C]Aminopyrine Accumulation in Intact Gastric Glands. Gastric acid secretion is stimulated by gastrin, histamine, and acetylcholine via the receptors on the parietal or the enterochromaffin-like cell. These physiologic stimuli influence the intracellular cyclic AMP and Ca²⁺ levels, thus leading to relocation and activation of H⁺,K⁺-ATPase. Instead of the physiologic agonists, the membrane-permeant dibutyryl cAMP was used to stimulate receptor-independent acid secretion in isolated gastric glands. Accumulation of the weak base [dimethyl-amine-¹⁴C]aminopyrine ([¹⁴C]AP) in the acidic compartment of the canaliculi serves as an indirect measure of acid secretion and forms the basis of measurement of acid secretion in this in vitro model of the mammalian stomach. Intact gastric glands were prepared from anesthetized New Zealand rabbits (weight 2–3 kg) by high-pressure perfusion of the stomach, separation of the fundic mucosa, and subsequent collagenase digestion of fragments of the mucosa (Berglindh et al., 1976; Berglindh and Obrink, 1976). After the gastric glands were washed several times, they were suspended in Krebs-Henseleit solution containing 2 mg/ml rabbit serum albumin and 2 mg/ml glucose. Glands were incubated for 30 min at 37°C in a shaker bath (200 oscillations/min) in the presence of 0.125 µM [¹⁴C]AP (113 µCi/µmol) at pH 7.4. Glands were stimulated with 1 mM dibutyryl cAMP in absence or presence of soraprazan (concentration range 3 nM –100 µM). The reaction was stopped by centrifugation (10 s at 20,000g). After centrifugation, the accumulation of [¹⁴C]AP in the glands was calculated as follows: radioactivity was measured in an aliquot of the supernatant (200 µl) and in the precipitate after dissolution in 1 ml of 1 N NaOH. To calculate the amount of protein, the Eppendorf tubes were weighed empty, with protein (wet weight) and with freeze-dried protein (dry weight). This ratio of supernatant and pellet protein radioactivity was used to calculate the accumulation of [¹⁴C]AP in the glands. The inhibitor concentration required to achieve 50% inhibition (IC₅₀) of [¹⁴C]AP accumulation was determined by fitting the equation for the expected inhibition pattern to the data points.

Soraprazan Binding to Ion-Leaky Gastric H,K-ATPase. [³H]Soraprazan binding studies were carried out at 20°C. In saturation experiments to determine the K_d value, ion-leaky gastric vesicles (0.01–0.02 mg/ml) were resuspended in a buffer composed of 20 mM Tris-HCl, pH 7.0, 2 mM MgCl₂, and 2 mM ATP (pH 7.0 by Tris) in the presence of increasing concentrations of [³H]soraprazan (0.1 nM –1 µM). Nonspecific binding was determined in the presence of a 100 fold excess of unlabeled soraprazan over the concentration range of [³H]soraprazan used. The enzyme suspension (1 ml) was incubated at 20°C for 30 min and rapidly filtered through a nitrocellulose membrane filter (HAWP Millipore filter, 0.45 µm) prewet with a solution composed of 20 mM Tris-HCl, pH 7.0, 10% polyethylene glycol 3350 that was placed on top of a glass fiber filter. The membrane was washed five times with 2.5 ml of a buffer composed of 20 mM Tris-HCl, pH 7.0, and 10% polyethylene glycol 3350 to remove unbound inhibitor. The membrane was put into a 20-ml scintillation vial, dimethylacetamide (0.5 ml) was added to dissolve the membrane, and 14 ml of scintillation solvent was added and counted. Binding of [³H]soraprazan was determined by subtracting the non-specific binding of [³H]soraprazan, obtained in the presence of the 100-fold excess of nonradioactive soraprazan, from the amounts of [³H]soraprazan bound to the membrane in the absence of the cold inhibitor.

In KCl competition experiments, a fixed concentration of [³H]soraprazan (18 nM) was incubated in the presence of varying concentrations of KCl (0.001–300 mM) at 20°C for 30 min. An aliquot at a given concentration of KCl was taken out, and the radioactivity bound to the enzyme was measured as described above. All experiments were performed in triplicate or more, and the average of the results was used for analysis.

Na,K-ATPase Measurement. The Na,K-ATPase purified from rabbit kidney was purchased from Professor H. J. Apell (University of Konstanz, Konstanz, Germany). Inhibitor activity on the Na,K-ATPase was measured in the same way as the H,K-ATPase activity in ion-leaky gastric vesicles with the exception that NaCl was added at a 12 mM final concentration.

View larger version (10K): [in this window] [in a new window]   Fig. 1. Chemical structure of SCH28080 and of soraprazan [(7R,8R,9R)-2,3-dimethyl-8-hydroxy-7(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo-[1,2-h][1,7]-naphthyridine].

The experimental procedure has been described in detail elsewhere (Postius et al., 1991). Briefly, on the experimental day, the animals were supplied with an ambulatory pH meter containing a solid-state storage unit (Digitrapper pH100; Medtronic, Düsseldorf, Germany) and a programmable infusion pump (Panomat P; Disetronic, Burgdorf, Switzerland). Intragastric pH was measured by means of a combined pH-glass electrode (type 440-M3; Ingold, Urdorf, Switzerland) inserted into the gastric cannula. Gastric acid secretion was stimulated by continuous subcutaneous infusion of pentagastrin (6 µg/kg/h). Recording of intragastric pH started at 8 AM, and pentagastrin infusion began at 9 AM. At 10:30 AM, the animals received the test substance orally. The experiment was terminated at 7:30 AM the next day, and pH readings were transformed by the Polygram98 program (Medtronics) to yield individual 24-h pH profiles. With application of a second program (Stat-pHac2000; Leif Fransson, Karlskrona, Sweden), the individual pH profiles of one treatment group were processed to establish median pH for intervals of 10 min each. Calculation of the significance of the pH levels achieved was performed by use of nonparametric analysis according to the Kruskal-Wallis test. The statistical tools are included in StatpHac2000.

Drugs for dog studies were soraprazan granulate (ALTANA Pharma AG, Konstanz, Germany) and esomeprazole (Nexium MUPS; AstraZeneca Pharmaceuticals LP, Wilmington, DE). Oral administration of the calculated amounts per body weight was performed comparably for both drugs in hard gelatin capsules. Encapsulation has been demonstrated not to affect the release and absorption characteristics of enteric-coated omeprazol MUPS in man (Schaltenbrand et al., 2001). With each animal, a drug-free control run was done. The comparison of both drugs was done as a randomized intraindividual dose-response study with six animals. Oral doses were 1, 3, 9, and 27 µmol/kg.

Primers and Conditions for TaqMan PCR. Human RNAs were obtained from several sources: ABS (Basel, Switzerland), Ambion (Huntingdon, UK), Ardais Corp. (Lexington, MA), Biocat (Heidelberg, Germany), Stratagene (Amsterdam, The Netherlands), and AXXAM srl (Milan, Italy). The purity and integrity of all RNAs was assessed on the Agilent 2100 bioanalyzer with the RNA 6000 NanoChip reagent set (Agilent Technologies, Böblingen, Germany). Samples were treated with DNase to remove traces of contaminating genomic DNA. RNAs were quantified with the Nanodrop ND-1000 spectrophotometer (PEQLAB Biotechnologie GmbH, Erlangen, Germany) and then stored at –80°C. Additionally, the human tissue RNA collection from AXXAM srl in combination with AXXAM srl's TaqMan analysis service was used. RNA samples were exchanged, and TaqMan PCR procedures were cross-validated between ALTANA Pharma AG and AXXAM srl. RNAs for every tissue came from several independent donors from both sexes. RNA (1 µg) was reverse-transcribed using random hexanucleotide primers (Roche Applied Science, Mannheim, Germany), dNTPs (PCR 3 Mix; Larova, Teltow, Germany), and avian myeloblastosis virus (AMV) reverse transcriptase (Roche Molecular Biochemicals, Mannheim, Germany) at 42°C for 1 h. All cDNAs were diluted with Tris-HCl buffer (1 mM Tris and 0.1 mM EDTA pH 8.0, Ambion) to a final concentration of 2 ng/µl and stored at –20°C until further use. As a control for genomic DNA contamination each RNA sample was incubated also in the absence of avian myeloblastosis virus reverse transcriptase, and this sample was run alongside in the TaqMan PCR runs. All primers and VIC-labeled probes were obtained from Applied Biosystems (Darmstadt, Germany). The assay on demand HS00167575_m1 was used for specific detection of the gastric H,K-ATPase subunit. The following endogenous 18S rRNA control primers and probe were used: sense 5'-CGGCTACCACATCCAAGGAA-3', antisense 5'-GCTGGAATTACCGCGGCT-3', and probe 5'-VIC-TGCTGGCACCAGACTTGCCCTC-TAMRA-3'.

TaqMan PCRs were run on ABI 7900 HT and ABI 7700 Sequence Detection Systems (Applied Biosystems). Each PCR reaction was performed in a total volume of 25 µl, containing 2.5 µl of cDNA, 12.5 µl of qPCR Mastermix Plus (Eurogentec, Seraing, Belgium), 1.25 µl of the commercial primer/probe set, and nuclease-free water (Ambion) in 96-well plate format. 18S rRNA primers and probe were used at 50 nM each. The TaqMan PCR parameters were 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of amplification (95°C denaturation for 20 s and 60°C annealing/extension for 1 min). Each run included a water control to check for DNA contamination and probe degradation. All PCRs were performed in triplicate for each sample. Expression levels were calculated from Ct with expression in stomach fundus being normalized to 100%·

Immunohistochemistry. Paraffin-embedded human normal tissue slides were supplied by Biocat and DCS (Hamburg, Germany) and were stained as follows in brief. After deparaffination and rehydration to DCS LabLine buffer (AL120R500; DCS), tissue slides were treated with protease (8038; Sigma, Munich, Germany). Slides were blocked with dual endogenous enzyme block (S2003; Dako, Hamburg, Germany) followed by a biotin blocking system (X0590; Dako). Then samples were blocked with 10% normal donkey serum (017-000-001; Dianova, Hamburg, Germany) in Tris-buffered saline. Monoclonal antibody 1H9 (D031-3; MoBiTec, Göttingen, Germany) directed against gastric H,K-ATPase subunit was used 1:2000 in common antibody diluent (HK156-5K) from DCS with 5% donkey serum. An isotype control antibody was used as negative control (N1698; Dako). Secondary biotin-SP-conjugated Affini Pure donkey anti-mouse IgG (715-065-150; Dianova) was used at 1:1000. Alkaline phosphatase was introduced by use of the StreptABC complex system from Dako (K0391). Signal was visualized with Sigma Fast Red (F4648) and samples were counterstained with ChemMate hematoxylin (S2020; Dako). Tissue slides were mounted on Kaiser glycerin gelatin (109242; Merck, Darmstadt, Germany). Microscopic pictures were taken with an Axiovert 200 microscope from Carl Zeiss (Göttingen, Germany) in combination with Zeiss AxioVision software (version 4.5).

View larger version (12K): [in this window] [in a new window]   Fig. 2. Lineweaver-Burk plot, showing the data used for Ki determination with ion-leaky gastric vesicles. The control line without inhibitor indicates a Km for potassium of 0.57 mM, which is in accord with the literature.

View larger version (11K): [in this window] [in a new window]   Fig. 3. Reversibility of inhibition by soraprazan. Activity of H,K-ATPase was measured in the presence and absence of 2.5 µM soraprazan as the starting concentration. Upon dilution by 2-, 5-, 10-, 20-, 50- or a 100-fold in assay buffer with constant potassium at 1 mM, H,K-ATPase activity in presence of soraprazan returned to almost 100% of control because of dissociation of soraprazan. For each dilution, activity without inhibitor was set as 100% control. Activity in the undiluted reaction was 2.8 nmol of phosphate/h · µg of protein with 2.5 µM soraprazan.

View larger version (21K): [in this window] [in a new window]   Fig. 4. A, gastric vesicles (11 µg/ml) were incubated in a buffer composed of 20 mM Tris-HCl, pH 7.0, 2 mM MgCl2, 2 mM ATP (pH 7.0 by Tris), and nigericin (2 µg/ml), in the presence of soraprazan. Soraprazan bound to the enzyme was determined as described under Materials and Methods. A Bmax of 2.89 ± 0.1 nmol/mg protein was obtained at 20°C. B, soraprazan binding was determined at 20°C in the presence of 2 mM Mg-ATP. The intact gastric vesicles curve represents incubation in the absence of nigericin and the leaky vesicle curve represents incubation in the presence of nigericin. The enzyme (10 µg/ml) was incubated in a buffer composed of 20 mM Tris-HCl, pH 7.0, 2 mM MgCl2, 2 mM ATP, ±5 µg of nigericin/ml, 18 nM [3H]soraprazan, and KCl (0.001–300 mM). No effect of KCl addition was seen in this experiment in the absence of nigericin. In contrast, in the presence of nigericin, a Km(app) of 5.2 mM KCl in the presence of 18 nM soraprazan was observed. Each measurement was an average of three experiments.

View larger version (18K): [in this window] [in a new window]   Fig. 5. A proton gradient was created in intact vesicles by gastric H,K-ATPase as soon as the enzymatic reaction was started by ATP. Upon addition of the inhibitors (indicated by arrow), inhibition by soraprazan occurred instantaneously, whereas esomeprazole showed the typical delay of acid-dependent activation of a PPI. The inhibition by soraprazan reached its half-maximal level in <5 min after addition of the inhibitor. This immediate and acid-independent mechanism of inhibition is observed with reversible interaction of a substrate with an enzyme. Esomeprazole reached half-maximal inhibition only within hours in this leaky vesicle system. Furthermore, soraprazan displayed a higher pH elevation in this system. Diagrams show arbitrary units (a.u.) over time, which represent relative intravesicular pH values.

Chemicals. Soraprazan and esomeprazole [6-methoxy-2-((S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl)-1H-benzimidazole] were obtained from ALTANA Chemical Research. [³H]Soraprazan (specific activity 30 Ci/mmol) was obtained from Amersham. Ionophores were dissolved in methanol. Soraprazan and esomeprazole were dissolved in dimethyl sulfoxide. These solvents were shown not to affect ATPase activity in any assay at the concentrations used. All other reagents were analytical grade or better.

	Results

Top Abstract Methods and Materials Results Discussion References

 
Structure-Activity Relationship of Naphthyridines versus Imidazopyridine. Soraprazan with the benzene ring orthogonal to the imidazopyridine (Fig. 1) was synthesized as described previously (Senn-Bilfinger et al., 2006). The generation of a relatively rigid bridged structure such as a naphthyridine, promised greater efficacy and more metabolic stability than the more flexible SCH28080.

Soraprazan Is Highly Potent in Vitro. Soraprazan is a potent inhibitor of gastric H,K-ATPase. It has an IC₅₀ of 0.1 µM when measured in ion-leaky vesicles in the presence of 1 mM potassium. Soraprazan also effectively inhibits dibutyryl cAMP-stimulated [¹⁴C]AP accumulation in isolated gastric glands with an IC₅₀ of 0.19 µM (0.09–0.40 µM geometric mean from n = 6 with 95% confidence limits), which is similar to the IC₅₀ (0.2 µM) found for SCH28080, the first of the reversible proton pump inhibitors with an imidazo[1,2] pyridine structure (Wallmark et al., 1987).

Kinetics of Soraprazan on the Gastric H,K-ATPase. The Lineweaver-Burk plot shown in Fig. 2 demonstrates that, in ion-leaky vesicles, soraprazan is a potent K⁺-competitive inhibitor of the H,K-ATPase. The K_i of soraprazan for inhibition of the H,K ATPase is 6.4 nM (arithmetic mean from four separate experiments). From one of these experiments, the K⁺-competitive characteristic of inhibition was derived (Fig. 2). The validity of this experiment was demonstrated by K_m determination for potassium from the same data of 0.57 mM. Soraprazan binds to the H,K-ATPase in ion-leaky vesicles with a K_d of 26.4 ± 3.4 nM and a B_max of 2.89 nmol/mg. This result was very similar to that found for intact vesicles (K_i, 47 nM; K_d, 30.9 nM) (Shin et al., 2005). The binding of soraprazan in the presence of 2 mM Mg-ATP (K_d 28.45) was in agreement with the K_i of 6.4 nM (K_i, 47 nM; K_d, 30.9 nM) (Shin et al., 2005). Comparable data for SCH28080 have been published (K_d, 45 nM; K_i, 24 nM) (Wallmark et al., 1987; Keeling et al., 1988, 1989).

View larger version (28K): [in this window] [in a new window]   Fig. 6. Relative expression of the gastric H,K-ATPase subunit in human organs/tissues with significantly detectable expression. Expression was detected by TaqMan PCR, and mean values and S.D. were calculated from Ct. The mean of stomach fundus was set as 100%. The number of independent donors measured was stomach cardia, n = 3; fundus, n = 12; corpus, n = 4; antrum, n = 3; pyloric sphincter, n = 3; pancreas, n = 7; adrenal gland, n = 4; adrenal gland cortex, n = 2; adrenal gland medulla, n = 2; and cerebellum, n = 4.

Additionally, the radioactive binding experiments demonstrate that potassium can displace the radiolabeled soraprazan from its binding site (Fig. 4). There was a concentration-dependent displacement of drug binding by K⁺ in the presence of nigericin. KCl did not displace drug binding in intact vesicles because the cation does not access the luminal drug binding site. However, in the presence of the ionophore nigericin, KCl displaced the drug, because K⁺ was able to reach the luminal surface of the enzyme, the location of the inhibitor binding site. There was a concentration-dependent displacement of drug binding by K⁺ in the presence of nigericin. The K_m(app) was 5.2 mM at 18 nM soraprazan. This shows that binding of soraprazan interferes with binding of K⁺ to the luminal binding site as previously found for SCH28080 (Keeling et al., 1988, 1989; Shin et al., 2005).

Soraprazan Is Highly Selective for H,K-ATPase. Soraprazan has a high selectivity for the H,K-ATPase versus the Na,K-ATPase. The K_i for inhibition of the Na,K-ATPase was found to be 14.6 µM (arithmetic mean from three separate experiments). The geometric mean ± S.D –log K_i was 4.83 ± 0.06 M. This compares with a K_i of 6.4 nM for the H,K-ATPase, demonstrating a selectivity for the latter by a factor of >2000.

Rate of Inhibition by Soraprazan. As demonstrated in Fig. 5, soraprazan inhibits H,K-ATPase immediately without a lag phase. This is the expected result for inhibitors of an enzyme that do not require activation. Upon addition of the compound (arrow) soraprazan immediately raised the intravesicular pH. This rapid inhibition is independent of intravesicular pH. Esomeprazole, in contrast, showed the typical delayed inhibition of a pH-activated PPI with 3 h between compound addition and half-maximal inhibition in this assay system (Shin et al., 2004).

Gastric H,K-ATPase Is a Stomach-Specific Target. The following human organs, tissues, and cells were tested for expression of gastric H,K-ATPase and subunits, namely, parts of the gastrointestinal tract from esophagus to colon, kidney, eye, retinal pigment epithelium, pancreas, adrenal gland, skeletal muscle, breast, ovary, placenta, uterus, fallopian tube, lymph node, spleen, heart, tongue, skin, liver, bladder, trachea, bronchus, lung, different parts of the central and peripheral nervous system, testis, prostate, different blood vessels, various adipose tissues, parotid and thyroid gland, white blood cells, thymus, tonsil, bone marrow, and larynx. Figure 6 shows the results for only the organs and tissues in which the TaqMan PCR was positive for the subunit of H,K-ATPase. Displayed are all organs/tissues with 0.2% of the H,K-ATPase subunit expression found in stomach fundus. It can be seen that subunit expression is maximal in stomach and marginally present in some other tissues. Not shown is the respective expression of the subunit, but the data were negative for adrenal gland and cerebellum. Because, without the subunit the subunit is unstable and degraded (Geering, 2001; Vagin et al., 2005), these results show that no significant expression of functional heterodimeric H,K-ATPase is present in organs other than gastric mucosa. These findings were confirmed on the protein level by immunohistochemistry with human tissue slides (Fig. 7). Whereas stomach fundus displayed a strong and very specific staining of the H,K-ATPase subunit in parietal cells, the adrenal gland was completely negative as was the concomitant isotype control.

View larger version (145K): [in this window] [in a new window]   Fig. 7. Immunohistologic staining of the gastric H,K-ATPase subunit in human paraffin tissue slides from stomach fundus (A) and adrenal gland (C) together with the respective isotype negative controls (B and D). The pictures clearly show that no specific staining and no unspecific background was observed in B, C, and D. Scale bar = 100 µm.

Superiority of Soraprazan over Esomeprazole in the Gastric Fistula Dog. In the gastric fistula dog in vivo model, the efficacy of compounds on acid secretion and thus on intragastric pH can be determined. Figure 8 shows the intragastric 24-h pH profiles of both compounds upon oral administration of 1, 3, 9, and 27 µmol/kg. Although both compounds elevate the intragastric pH in a dose-dependent manner, the very straight and clear pH profile of soraprazan differs strikingly from the inconsistent pH-elevating effect of esomeprazole. Statistics of the 24-h profiles are compiled in Table 1. Accordingly, mean times to pH 4 and 6 are fast with all doses of soraprazan (Fig. 8, a–d) but significantly later and highly variable with all doses of esomeprazole (Fig. 8, e–h). At 1 µmol/kg, only one animal reaches pH 4 but none reaches pH 6 with esomeprazole in contrast to three animals for soraprazan for both pH levels. The lowest dose of soraprazan produces pH 4 and 6 faster than any dose of esomeprazole used. The 22-h pH median achieves values of 3.7 and 6.7 at 9 and 27 µmol/kg soraprazan, whereas the same doses of esomeprazole yielded pH medians of 1.9 and 2.2. Neutral pH was reached with 3 and 27 µmol/kg soraprazan and esomeprazole, respectively; 3 µmol/kg soraprazan produces a very consistent intragastric pH-plateau (Fig. 8, b) that is statistically significant compared with controls (p < 0.01). In contrast, even 27 µmol/kg esomeprazole do not produce consistent and reliable intragastric neutrality (Fig. 8, h). Both onset of action and maximum pH reached are much more variable with esomeprazole, which here is clearly inferior to soraprazan (Fig. 7, e–h). No statistical significance against control (Fig. 7, a) could be detected for esomeprazole, whereas 6 h of significant pH elevation was found with soraprazan. A very common measure from clinical studies, the period of time at a pH greater than 4.0 (Bell et al., 1992), is 24.4, 49.6, and 87.4% versus 0, 15, and 35.2% for 3, 9, and 27 µmol/kg soraprazan and esomeprazole, respectively. In this model, soraprazan showed clear superiority over esomeprazole with respect to the extent and duration of pH elevation, speed of rise of pH, and interindividual variation.

View larger version (50K): [in this window] [in a new window]   Fig. 8. Dose-dependent effects of soraprazan and esomeprazole on intragastric 24-h pH profiles in the pentagastrin-stimulated gastric fistula dog. Abscissa, time of day; ordinate, intragastric pH. Intraindividual comparison with n = 6 dogs. The diagrams show medians (solid curves) and 25 and 75% quartiles (shaded areas). Continuous stimulation of acid secretion is done by s.c. infusion of pentagastrin from 9:00 AM to 7:30 AM on the next day (open frame in each diagram). Administration of drugs at 10:30 AM (): soraprazan (a–d) and esomeprazole (e–h). Oral doses were 1, 3, 9, and 27 µmol/kg. For statistical description of the 24-h pH profiles, see Table 1.

	Discussion

Top Abstract Methods and Materials Results Discussion References

 
Full control of gastric acid secretion has not yet been obtained in clinical practice. It is believed that full inhibition of secretion would alleviate, in particular, nocturnal acid breakthrough that may result in nocturnal symptoms or nocturnal GERD (Ang and Fock, 2006).

Although the PPIs of the substituted pyridyl methyl sulfinyl benzimidazole class treat most of the acid-related complications in the upper gastrointestinal tract, there is still a need to improve suppression of gastric acid secretion to obtain better symptom relief. The drawbacks of the PPIs relate to their mechanism of inhibition and the pharmacokinetics of this class of drugs. The mechanism of inhibition by PPIs requires food intake not less than h after administration of the drug because acid secretion in the secretory canaliculus of the parietal cell has to be induced by food via cholinergic and histaminergic pathways. Acidification on the luminal side of the pump in the membrane of the secretory canaliculus is necessary for accumulation of the PPI and then for the acid-catalyzed conversion of the PPI prodrugs into the active, thiophilic sulfenic acid form that is able to bind to various luminal cysteines of the H,K-ATPase, forming a covalent disulfide and thereby inhibiting the enzyme and, in consequence, acid secretion. Food stimulation of acid secretion and a plasma half-life of 1 h make the window for inhibition of active proton pumps very narrow. Acid secretion during day and night therefore cannot be controlled by once daily dosage of PPI in the morning. The mechanism of acid control by the PPIs also involves the dynamics of partial inhibition of the H,K-ATPase after the first dose only, the recovery of acid secretion during 24 h due to food activation of inactive H,K-ATPase, the reversal of inactivated enzyme (Huber et al., 1995), and the daily 25% de novo biosynthesis of new enzyme (Gedda et al., 1995; Shin and Sachs, 2002).

Therefore, a drug has been developed that can immediately and more completely inhibit the H,K-ATPase independent of food and time of administration, because at an adequate dose, no pump would escape inhibition. Soraprazan showed in vitro potency with an IC₅₀ of 0.19 µM in gastric glands and bound to the H,K-ATPase with a K_d of 28.27 nM. This value is close to the K_i for the enzyme. K⁺-competitive inhibition and full reversibility were shown, the latter by three independent methods (Lineweaver-Burk plot, dilution experiments, and reversal of radiolabeled compound binding). One main characteristic of these reversible inhibitors, the fast onset of action, could be shown impressively in vitro in comparison with esomeprazole (Fig. 5). Vesicles in this in vitro system do not acidify as much as do the canaliculi in vivo, and therefore esomeprazole is not activated at an adequate rate. However, even with faster activation of esomeprazole in vivo, soraprazan is expected to be faster in any system because of its mode of action independent of low pH. Because of the incomplete acidification of vesicles in this in vitro setting, this system emphasizes the advantage of acid-independent inhibition of P-CABs over PPIs. Selectivity against Na,K-ATPases and other ATPases by a factor of >2000 along with the exclusive expression of gastric H,K-ATPase demonstrated in human stomach suggests that no effects on ATPase-mediated H⁺ or K⁺ homeostasis in other organs should be found.

Soraprazan demonstrated an impressive in vivo efficacy and superiority to esomeprazole in the fistula dog model. Standard deviations for esomeprazole were always much higher, which translates into higher interindividual variations in dogs and probably also in patients. The in vivo results in the dog clearly show the dose-independent duration of action of esomeprazole. With PPIs, the time of acid inhibition is achieved by blockade of stimulated parietal cells. Because of the short half-life of 0.5 h in dog, an increase in dose does not lead to prolonged duration of action. In contrast, inhibition of acid secretion by soraprazan is not dependent on active parietal cells but rather on the availability of effective plasma concentrations. Therefore, an increasing dose of soraprazan leads to prolongation of pH elevation as seen in classic receptor pharmacology. It is of note that the relation of the half-lives of soraprazan and esomeprazole (2.7 and 1.1 h; R. Huber, unpublished data) is comparable in humans. Therefore, it is likely that the relative effects of both compounds in humans are comparable to those seen in dogs on day 1.

Soraprazan is a potent and reversible inhibitor of the H,K-ATPase and introduces a new class of drugs for therapy of acid-related diseases. There is an increasing awareness of unmet medical needs in GERD therapy today, in particular, complete relief from heartburn, day and night. P-CABs may fulfill this goal for acid-related pain in GERD by raising the intragastric pH to a reliable plateau of pH 6 to 7 and therefore quickly eliminating pain caused by acid reflux into the esophagus. In addition to bringing fast symptom relief to patients with GERD, these effects are expected to be of great value for treating gastrointestinal bleeding and producing pain relief in intensive care patients. The pharmacology of compounds in this class with a fast onset of action favors them for on-demand use in clinical practice. With soraprazan, therefore, it is possible to effectively ablate gastric acid secretion for any period of time. This ablation would eliminate the problems associated with PPIs, such as nocturnal acid breakthrough, and also allow rational on-demand therapy (Sachs et al., 2002; Ang and Fock, 2006). The immediate and profound inhibition of acid secretion, as shown for soraprazan, promises significant improvement in therapeutic efficacy over PPIs in acid-related diseases.

	Footnotes

 
W.A.S. and M.H. contributed equally to this work.

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

doi:10.1124/jpet.107.120428.

ABBREVIATIONS: GERD, gastroesophageal reflux disease; PPI, proton pump inhibitor; soraprazan, BYK61359, (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo-[1,2-h][1,7]-naphthyridine; P-CAB, potassium-competitive acid blocker; PIPES, piperazine-N,N'-bis(2-ethanesulfonic acid); [¹⁴C]AP, [dimethyl-amine-¹⁴C]aminopyrine; MUPS, multiple unit pellet system; PCR, polymerase chain reaction; esomeprazole, 6-methoxy-2-((S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl)-1H-benzimidazole.

Address correspondence to: Dr. Michael Herrmann, Department of Biochemistry Gastroenterology, ALTANA Pharma AG, Byk-Gulden Strasse 2, 78467 Konstanz, Germany. E-mail: michael.herrmann{at}altanapharma.com

	References

Top Abstract Methods and Materials Results Discussion References

 

Ang TL and Fock KM (2006) Nocturnal acid breakthrough: clinical significance and management. J Gastroenterol Hepatol 21 (Suppl 5): 125–128.[CrossRef]

Beil W, Hackbarth I, and Sewing KF (1986) Mechanism of gastric antisecretory effect of SCH 28080. Br J Pharmacol 88: 19–23.[Medline]

Bell NJ, Burget D, Howden CW, Wilkinson J, and Hunt RH (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51 (Suppl 1): 59–67.[Medline]

Berglindh T, Helander HF, and Obrink KJ (1976) Effects of secretagogues on oxygen consumption, aminopyrine accumulation and morphology in isolated gastric glands. Acta Physiol Scand 97: 401–414.[Medline]

Berglindh T and Obrink KJ (1976) A method for preparing isolated glands from the rabbit gastric mucosa. Acta Physiol Scand 96: 150–159.[Medline]

Bytzer P and Blum AL (2004) Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 20: 389–398.[CrossRef][Medline]

DiPalma JA (2001) Management of severe gastroesophageal reflux disease. J Clin Gastroenterol 32: 19–26.[CrossRef][Medline]

Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55: 170–171.[Medline]

Ganser AL and Forte JG (1973) K⁺-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochim Biophys Acta 307: 169–180.[Medline]

Gedda K, Scott D, Besancon M, Lorentzon P, and Sachs G (1995) Turnover of the gastric H⁺,K⁺-adenosine triphosphatase subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 109: 1134–1141.[CrossRef][Medline]

Geering K (2001) The functional role of subunits in oligomeric P-type ATPases. J Bioenerg Biomembr 33: 425–438.[CrossRef][Medline]

Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, and Sturm E (1995) Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 9: 363–378.[Medline]

Im WB, Blakeman DP, Mendlein J, and Sachs G (1984) Inhibition of (H⁺+K⁺)-ATPase and H⁺ accumulation in hog gastric membranes by trifluoperazine, verapamil and 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate. Biochim Biophys Acta 770: 65–72.[Medline]

Keeling DJ, Laing SM, and Senn-Bilfinger J (1988) SCH 28080 is a lumenally acting, K⁺-site inhibitor of the gastric (H⁺+ K⁺)-ATPase. Biochem Pharmacol 37: 2231–2236.[CrossRef][Medline]

Keeling DJ, Taylor AG, and Schudt C (1989) The binding of a K⁺ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (H⁺ + K⁺)-ATPase. J Biol Chem 264: 5545–5551.[Abstract/Free Full Text]

Klinkenberg-Knoll EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, et al. (2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118: 661–669.[CrossRef][Medline]

Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275.[Free Full Text]

Mendlein J and Sachs G (1990) Interaction of a K⁺-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H⁺,K⁺-ATPase. J Biol Chem 265: 5030–5036.[Abstract/Free Full Text]

Postius S, Brauer U, and Kromer W (1991) The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog. Life Sci 49: 1047–1052.[CrossRef][Medline]

Rabon E, Chang H, and Sach G (1978) Quantitation of hydrogen ion and potential gradients in gastric plasma membrane vesicles. Biochemistry 17: 3345–3353.[CrossRef][Medline]

Rabon EC, Im WB, and Sachs G (1988) Preparation of gastric H⁺,K⁺-ATPase. Methods Enzymol 157: 649–654.[Medline]

Sachs G (2001) Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 13 (Suppl 1): 35–41.

Sachs G (2003) Physiology of the parietal cell and therapeutic implications. Pharmacotherapy 23: 68–73.[CrossRef]

Sachs G, Chang HH, Rabon E, Schackman R, Lewin M, and Saccomani G (1976) A nonelectrogenic H⁺ pump in plasma membranes of hog stomach. J Biol Chem 251: 7690–7698.[Abstract/Free Full Text]

Sachs G, Shin JM, and Howden CW (2006) Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23 (Suppl 2): 2–8.[CrossRef][Medline]

Sachs G, Shin JM, Vagin O, Munson K, Weeks D, Scott DR, and Voland P (2002) Current trends in the treatment of upper gastrointestinal disease. Best Pract Res Clin Gastroenterol 16: 835–849.[CrossRef][Medline]

Schaltenbrand R, Huber R, Cotoraci CA, Mascher H, Potthast H, and Hole U (2001) Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule. Int J Clin Pharmacol Ther 39: 453–459.[Medline]

Senn-Bilfinger J, Ferguson JR, Holmes MA, Lumbard KW, Huber R, Zech K, Hummel RP, and Zimmermann PJ (2006) Glucuronide conjugates of soraprazane (BY359), a new potassium-competitive acid blocker (P-CAB) for treatment of acid-related diseases. Tetrahedron Lett 47: 3321–3323.[CrossRef]

Shin JM, Cho YM, and Sachs G (2004) Chemistry of covalent inhibition of the gastric (H⁺,K⁺)-ATPase by proton pump inhibitors. J Am Chem Soc 126: 7800–7811.[CrossRef][Medline]

Shin JM, Grundler G, Senn-Bilfinger J, Simon WA, and Sachs G (2005) Functional consequences of the oligomeric form of the membrane-bound gastric H,K-ATPase. Biochemistry 44: 16321–16332.[CrossRef][Medline]

Shin JM and Sachs G (2002) Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 123: 1588–1597.[CrossRef][Medline]

Stewart B, Wallmark B, and Sachs G (1981) The interaction of H⁺ and K⁺ with the partial reactions of gastric H⁺ and K⁺ ATPase. J Biol Chem 256: 2682–2690.[Abstract/Free Full Text]

Stolte M, Vieth M, Schmitz JM, Alexandridis T, and Seifert E (2000) Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol 35: 1125–1130.[CrossRef][Medline]

Teyssen S, Singer MV, Pfützer R, Heinze H, and Fischer R (2001) Reliable acid suppression with pantoprazole contrasts with rapid development of tolerance to ranitidine in healthy individuals. Clin Drug Investig 21: 273–279.[CrossRef]

Vagin O, Denevich S, Munson K, and Sachs G (2002) SCH28080, a K⁺-competitive inhibitor of the gastric H,K-ATPase, binds near the M5–6 luminal loop, preventing K⁺ access to the ion binding domain. Biochemistry 41: 12755–12762.[CrossRef][Medline]

Vagin O, Munson K, Denevich S, and Sachs G (2003) Inhibition kinetics of the gastric H,K-ATPase by K-competitive inhibitor SCH28080 as a tool for investigating the luminal ion pathway. Ann NY Acad Sci 986: 111–115.[Medline]

Vagin O, Turdikulova S, Yakubov I, and Sachs G (2005) Use of the H,K-ATPase subunit to identify multiple sorting pathways for plasma membrane delivery in polarized cells. J Biol Chem 280: 14741–14754.[Abstract/Free Full Text]

von Büdingen C, Boer R, Sachs G, and Simon WA (1996) Reversible binding of acid pump antagonist to the gastric H,K-ATPase. Gastroenterology 110: A287.

Wallmark B, Briving C, Fryklund J, Munson K, Jackson R, Mendlein J, Rabon E, and Sachs G (1987) Inhibition of gastric H⁺,K⁺-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole. J Biol Chem 262: 2077–2084.[Abstract/Free Full Text]

Wolosin JM and Forte JG (1981) Functional differences between K⁺-ATPase rich membranes isolated from resting or stimulated rabbit fundic mucosa. FEBS Lett 125: 208–212.[CrossRef][Medline]

Yoda A and Hokin LE (1970) On the reversibility of binding of cardiotonic steroids to a partially purified (Na+K)-activated adenosinetriphosphatase from beef brain. Biochem Biophys Res Commun 40: 880–886.[CrossRef][Medline]

This article has been cited by other articles:

				H. Mori, H. Tonai-Kachi, Y. Ochi, Y. Taniguchi, H. Ohshiro, N. Takahashi, T. Aihara, A. Hirao, T. Kato, M. Sakakibara, et al. N-(2-Hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a Novel, Potent, and Selective Acid Pump Antagonist for the Treatment of Gastroesophageal Reflux Disease J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 671 - 679. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.107.120428v1 321/3/866    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simon, W. A. Articles by Postius, S. Search for Related Content PubMed PubMed Citation Articles by Simon, W. A. Articles by Postius, S.